Core 2: Mouse and Human Molecular Imaging
Core 2: Mouse and Human Molecular Imaging
批准号:
10218107
负责人:
Henry Charles Manning
金额:
$24.1万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-09 至 2024-05-31
关键词:
BioinformaticsBiologicalBiometryCancer CenterClinical ResearchColorectal CancerCoupledCustomCyclic GMPDataData AnalysesDevelopmentDigital X-RayEquipmentFeasibility StudiesFunctional ImagingFutureGenomic approachGoalsHumanHuman ResourcesImageIndividualInfrastructureMagnetic Resonance ImagingMalignant neoplasm of gastrointestinal tractMeasuresMissionMolecularMolecular ProbesMusOpticsPathologyPhenotypePilot ProjectsPlayPositron-Emission TomographyQuality ControlRadiochemistryResearchResearch PersonnelResource DevelopmentResourcesRoleSpecimenTissuesTranslational ResearchWorkX-Ray Computed Tomographyanatomic imaginganimal imagingbasedata de-identificationgastrointestinalimaging biomarkerimaging facilitiesimaging modalityliquid biopsymolecular imagingnovelpre-clinicalpre-clinical researchresearch studysingle photon emission computed tomographytumor
中文摘要
项目摘要/摘要:鼠标和人类分子成像核心
老鼠和人类分子成像(MHMI)核心将在翻译研究中发挥核心作用
范德比尔特-英格拉姆癌症中心(VICC)在胃肠道(GI)癌症中的使命,提供
三个项目的最先进的成像资源,未来的试点和可行性研究,以及开发
研究。MHMI核心将利用现有的、机构支持的设备和基础设施来提供
全方位的小动物和人类功能、分子和解剖成像资源,包括
磁共振成像(MRI)、计算机断层扫描(CT)、数字X射线、光学、单光子发射
计算机断层扫描(SPECT)和正电子发射断层扫描(PET)。这一核心的一个独特功能是VICC
GI孢子调查员还将获得新的探针开发资源,这些资源利用
范德比尔特分子探测器中心(CMP)的能力,包括高通量、面向多样性
适合开发新型成像化合物的合成能力,以及世界级的临床前和
CMP放射化学设施的cGMP资源。MHMI有三个具体目标:目标1.为了发展,
优化并提供结直肠癌定量替代分子成像生物标记物
支持临床前和临床研究;目标2.为定制的成像数据分析提供支持
特定于项目的应用,包括多种成像模式的联合注册和集成,以及
作为所有临床前和临床研究研究的一部分执行的质量控制指标;目标3.工作
以组织病理学和细胞分析(TPCA)为核心,以生物统计学和生物信息学为核心
(BBC)建立请求联网、样本跟踪、提取未确认身份的核心战略
与成像、生物显微镜和其他研究数据相关的数据。翻译目标:分子成像
大有希望阐明单个肿瘤的细胞和分子基础。互补于
基因组学方法,分子成像提供了一种对肿瘤“表型”的定量的、功能性的测量,并且,
当与其他基于组织的或较新的“液体”活检方法相结合时,可以提供丰富的生物学
有关个别肿瘤的信息。MHMI核心将为VICC GI孢子调查人员提供一种机制
以及通过使用以下工具推进CRC前沿翻译研究所需的专家人员
老鼠和人类的非侵入性分子成像。
英文摘要
PROJECT SUMMARY/ABSTRACT: Mouse and Human Molecular Imaging Core
The Mouse and Human Molecular Imaging (MHMI) Core will play a central role in the translational research
mission of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Gastrointestinal (GI) Cancer, providing
state-of-the-art imaging resources for three projects, future pilot and feasibility studies, and developmental
research. The MHMI Core will leverage existing, institutionally-supported equipment and infrastructure to offer
a full range of small animal and human functional, molecular, and anatomical imaging resources, including
magnetic resonance imaging (MRI), computed tomography (CT), digital X-ray, optical, single photon emission
computed tomography (SPECT), and positron emission tomography (PET). A unique feature of this core, VICC
GI SPORE investigators will also have access to novel probe development resources that leverage the
capabilities of the Vanderbilt Center for Molecular Probes (CMP), including high-throughput, diversity-oriented
synthesis capabilities suitable for developing novel imaging compounds, as well as world-class preclinical and
cGMP resources of the CMP radiochemistry facility. The MHMI has three Specific Aims: Aim 1. To develop,
optimize, and provide quantitative surrogate molecular imaging biomarkers of colorectal cancer (CRC) for
support of preclinical and clinical research; Aim 2. To provide support for imaging data analysis customized to
project-specific applications, including co-registration and integration of multiple imaging modalities, along with
quality control metrics to be performed as part of all preclinical and clinical research studies; Aim 3. To work
with both the Tissue Pathology and Cellular Analysis (TPCA) Core and the Biostatistics and Bioinformatics
(BBC) Core to establish strategies for networking of requests, specimen tracking, extraction of de-identified
data relating to imaging, biospecimens, and other research data. Translational goal: Molecular imaging holds
great promise to illuminate the cellular and molecular underpinnings of individual tumors. Complementary to
genomic approaches, molecular imaging provides a quantitative, functional measure of tumor `phenotype', and,
when coupled with other tissue-based or newer `liquid' biopsy approaches, can provide a wealth of biological
information about individual tumors. The MHMI Core will provide VICC GI SPORE investigators a mechanism
and the expert personnel required for advancing cutting-edge translational research in CRC through the use of
non-invasive molecular imaging in mice and humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Quantitative Imaging of OXPHOS in Pancreatic Cancer
-
批准号:10649885
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2023
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:9890526
-
项目类别:
-
资助金额:$58.58万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:10687038
-
项目类别:
-
资助金额:$57.72万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)
-
批准号:10267667
-
项目类别:
-
资助金额:$58.74万
-
财政年份:2020
-
负责人:Henry Charles Manning
-
依托单位:
Core 2: Mouse and Human Molecular Imaging
-
批准号:10443609
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2019
-
负责人:Henry Charles Manning
-
依托单位:
Core 2: Mouse and Human Molecular Imaging
-
批准号:10700844
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2019
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:9085233
-
项目类别:
-
资助金额:$45.27万
-
财政年份:2016
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:9248709
-
项目类别:
-
资助金额:$17.89万
-
财政年份:2016
-
负责人:Henry Charles Manning
-
依托单位:
Imaging Core
-
批准号:8764764
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2014
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8881115
-
项目类别:
-
资助金额:$27.39万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8371615
-
项目类别:
-
资助金额:$45.27万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
TSPO Ligands for Cancer Imaging
-
批准号:8529474
-
项目类别:
-
资助金额:$42.56万
-
财政年份:2012
-
负责人:Henry Charles Manning
-
依托单位:
Dedicated Quantitative Fluorescence Tomography System for Small Animal Imaging
-
批准号:7794463
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2010
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8494590
-
项目类别:
-
资助金额:$28.85万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Molecular Determinants Affecting FLT-PET in Colorectal Cancer
-
批准号:7944026
-
项目类别:
-
资助金额:$49.86万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:7699155
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8192915
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Molecular Determinants Affecting FLT-PET in Colorectal Cancer
-
批准号:7816526
-
项目类别:
-
资助金额:$49.96万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Biological Basis of Imaging Biomarkers in Colorectal Cancer
-
批准号:8305039
-
项目类别:
-
资助金额:$30.7万
-
财政年份:2009
-
负责人:Henry Charles Manning
-
依托单位:
Synergizing Quantitative HTS Technologies to Guide MIA Discovery and Development
-
批准号:8042612
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2008
-
负责人:Henry Charles Manning
-
依托单位:
海外基金